These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37741432)

  • 1. Editorial: The progress and challenges of hematological malignancies in the era of big data and new therapy.
    Hu H
    Cancer Lett; 2023 Oct; 575():216399. PubMed ID: 37741432
    [No Abstract]   [Full Text] [Related]  

  • 2. Guest editorial: advances in immunotherapy for hematological malignancies.
    Kadowaki N
    Int J Hematol; 2018 Mar; 107(3):260-261. PubMed ID: 29427173
    [No Abstract]   [Full Text] [Related]  

  • 3. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.
    Westin GF; Dias AL; Go RS
    Curr Hematol Malig Rep; 2016 Aug; 11(4):271-9. PubMed ID: 27177742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary and Integrative Medicine in Hematologic Malignancies: Questions and Challenges.
    Frenkel M; Sapire K
    Curr Oncol Rep; 2017 Oct; 19(12):79. PubMed ID: 29032389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adapted physical activity and hematological malignancies.
    Bouanani N; Asly M
    Pan Afr Med J; 2020; 37():168. PubMed ID: 33425201
    [No Abstract]   [Full Text] [Related]  

  • 7. Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies.
    Mehta PA; Rotz SJ; Majhail NS
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):e11-e19. PubMed ID: 30244107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL).
    Yamaguchi M; Suzuki R
    Int J Hematol; 2019 Apr; 109(4):371-376. PubMed ID: 30820835
    [No Abstract]   [Full Text] [Related]  

  • 9. Ac-SDKP: linking cardiac remodeling to hematological malignancies.
    Caers J; Vanderkerken K
    Leuk Lymphoma; 2006 Sep; 47(9):1732-3. PubMed ID: 17064980
    [No Abstract]   [Full Text] [Related]  

  • 10. Progress on CAR-T cell therapy for hematological malignancies.
    Hu K; Huang Y; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):192-203. PubMed ID: 36161291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.
    Di Martino MT; Zazzeroni F; Donadelli M; Chiodoni C; Caraglia M; Scotlandi K; Meschini S; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):48. PubMed ID: 29506548
    [No Abstract]   [Full Text] [Related]  

  • 12. [The progress of targeted therapy of hematological malignancies in recent 10 years].
    Wang L; Shen ZX
    Zhonghua Nei Ke Za Zhi; 2013 Feb; 52(2):121-3. PubMed ID: 23967604
    [No Abstract]   [Full Text] [Related]  

  • 13. The Society of Hematologic Oncology (SOHO): moving forward in the battle against hematologic malignancies.
    Freireich EJ
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):385. PubMed ID: 23158093
    [No Abstract]   [Full Text] [Related]  

  • 14. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent progress in therapy for hematological malignancies].
    Naoe T; Kinoshita T
    Nihon Naika Gakkai Zasshi; 2006 Mar; 95(3):534-7. PubMed ID: 16640088
    [No Abstract]   [Full Text] [Related]  

  • 16. Gene therapy for hematological malignancies.
    Schmidt-Wolf GD; Schmidt-Wolf IG
    Clin Exp Med; 2003 May; 3(1):4-14. PubMed ID: 12748873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guest editorial: Immunotherapy for hematological malignancies: the quest to overcome tolerogenic drive.
    Kadowaki N
    Int J Hematol; 2014 Feb; 99(2):105-6. PubMed ID: 24395282
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hematologic malignancies/pediatric malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2009 May; 36(5):742-3. PubMed ID: 19496282
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status of molecular targeted therapy for hematologic malignancies: introduction.
    Ueda T
    Int J Clin Oncol; 2014 Feb; 19(1):1-2. PubMed ID: 24357412
    [No Abstract]   [Full Text] [Related]  

  • 20. [Advances in the target therapy of hematological malignancies].
    Niu T; Liu T
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):642-6. PubMed ID: 25286692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.